RESMED
ResMed, a pioneer and global leader in sleep and respiratory medicine, has announced the launch of its ResMed Air Solutions range, led by the intelligent, cloud-enabled AirCurve 10 CS PaceWave™ with AirView system. This is the first device to combine remote monitoring with ResMed’s innovative PaceWave™ Minute Ventilation (MV)-Adaptive-Servo-Ventilation (ASV) therapy. Through a unique patented algorithm, PaceWaveTM MV-ASV allows a patient’s breathing during sleep to be intelligently stabilised and monitored, offering an option to treat a wide variety of patients with central sleep apnoea (CSA), a specific form of sleep-disordered breathing. This is especially relevant for those suffering from Cheyne-Stokes Respiration (CSR), a pattern of CSA commonly seen in patients with heart failure.1,2,3 CSA/CSR is thought to affect up to 50%4,5,6 of patients with chronic heart failure and has been linked to increased mortality and morbidity in this patient population.7 The use of PaceWaveTM MV-ASV therapy to treat CSA in patients with chronic heart failure is currently being investigated in SERVE-HF , the world’s largest randomised trial in this field.
Commenting on the launch of ResMed’s Air Solutions , Anne Reiser, President of ResMed Europe and Asia Pacific, said: “The launch of Air Solutions and the unique offering of the AirCurve 10 CS PaceWave TM with AirView represents a landmark shift in the treatment of central sleep apnoea. By combining ResMed-patented technology with new wireless monitoring capabilities, we are providing a solution that is both an effective therapy, and has potential to offer significant time and cost savings to physicians and health services.
“This launch may also have significant implications for many patients with chronic heart failure. The findings of the SERVE-HF study will indicate the scale of benefit PaceWaveTM MV-ASV may bring but there is real potential for a step-change on how we prioritise breathing management in this patient population.”
ResMed’s AirCurve 10 CS PaceWave™ is now available in select European countries.
About the SERVE-HF study
It is thought that around 14 million people in Europe are currently living with heart failure8 and that 30-50% are at risk of having concurrent central sleep-disordered breathing.4,5,6 SERVE-HF is the world’s largest randomised study to investigate if treating chronic heart failure patients who also have CSA with PaceWaveTM MV-ASV therapy may improve outcomes including mortality and morbidity. More than 1,325 patients have taken part in the study, which completed enrolment in 2013. More details on SERVE-HF can be found at www.servehf.com .
About ResMed
The global team at ResMed (NYSE:RMD) are united in their commitment to changing lives with every breath. With more than 4,000 employees and a presence in over 100 countries, the company has been pioneering new and innovative devices and treatments for sleep-disordered breathing, chronic obstructive pulmonary disease, and other key chronic diseases for more than 25 years. ResMed's world-leading products and innovative solutions improve the quality of life for millions of patients worldwide, reduce the impact of chronic disease, and save healthcare costs. For more information about ResMed and its businesses, visit www.resmed.com or follow @resmed on Twitter.
No. ENDS No.
1 Oldenburg O et al. Adaptive servoventilation improves cardiac function and respiratory stability. Clin Res Cardiol 2011;100(2):107–15.
2 Allam JS et al. Efficacy of adaptive servo-ventilation in treatment of complex and central sleep apnea syndromes.Chest 2007;132(6):1839–46.
3 Morgenthaler TI et al. Adaptive servo-ventilation versus noninvasive positive pressure ventilation for central, mixed, and complex sleep apnea syndromes. Sleep 2007;30(4):468–75.
4 Akiko Noda et al. Therapeutic Strategies for Sleep Apnea in Hypertension and Heart Failure. Pulmonary Medicine . 2013 Article ID 814169.
5 Olaf Oldenburg et al., Sleep-disordered breathing in patients with symptomatic heart failure, Eur J Heart Fail . 2006 doi:10.1016/j.ejheart.2006.08.003.
6 Paulino et al. Prevalence of sleep-disordered breathing in a 316-patient French cohort of stable congestive heart failure. Archives of Cardiovascular Disease . 2009; 102: 169-175.
7 Cowie et al. Sleep-Disordered Breathing in Heart Failure – Current State of the Art. Cardiac Failure Review (2015) Vol. 1 Issue 1.
8 Remme WJ et al. Public awareness of heart failure in Europe: first results from SHAPE. Eur Heart J . 2005; 26: 2413–2421.
Contact:
Reynolds-MacKenzie
Tim Cockroft
+44 207 861 2805
+44 7957
325 583
tim@reynoldsmackenzie.com
or
ResMed
Odile
Bigaignon
Cardiology Director, Europe
+33 426 100 245
+33
6 26 38 55 58
Odile.Bigaignon@resmed.com
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 07:00:00 CEST | Press release
- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI - Topline results expected in the second half of 2026 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P
Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 19:06:00 CEST | Press release
With Qi2.2 certification, Belkin reinforces its commitment to quality, safety, and performance for the next generation of wireless charging Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The comp
Cessna Grand Caravan EX to Feature New Executive Interior Options, Expanding Opportunities for Elevated Missions15.7.2025 18:05:00 CEST | Press release
The legendary Cessna Grand Caravan EX will now feature three new executive interior schemes for customers to select when designing their aircraft cabin. The Lunar, Obsidian and Saddle Sport interiors join the existing Canyon and Savanna schemes, providing a broader range of standard choices. The new interior options are available to customers starting this month and allow them to further tailor the interior of their aircraft based on their personal preference or mission. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715021096/en/ Cessna Grand Caravan EX to feature new executive interior options, expanding opportunities for elevated missions (Photo Credit: Textron Aviation) The Cessna Grand Caravan EX is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. Premium versions of each of the new interiors are also available, featuring quilted seat stitching and plush carpet, providing an elev
7 Million Tokens Sells Out in less than One Hour—$MBG Token Pre-Sale Shatters Expectations15.7.2025 17:27:00 CEST | Press release
MultiBank Group, the world’s largest and most regulated financial derivatives institution, has set a new benchmark in digital asset launches. The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715055611/en/ The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. Commenting on the success of the Pre-Sale, Naser Taher, Founder and Chairman of MultiBank Group, said: “The sell-out of our initial $MBG Token offering in less than one hour is a decisive validation of our vision. In a market saturated with speculation, the response we received confirms that institutional-grade transparency, regulatory integrity, and asset-backed value are what investors are now demanding. $MBG is here for the long term, reflecting t
First Patient Enrolled in National Cancer Institute’s Vanguard Study Evaluating Guardant Health’s Shield Multi-Cancer Detection Test15.7.2025 17:01:00 CEST | Press release
Study addressing feasibility of using multi-cancer detection tests in future trials aims to enroll up to 24,000 participantsShield MCD reviewed by FDA as part of NCI’s investigational device exemption (IDE) Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that patient enrollment has begun in the National Cancer Institute (NCI)’s Vanguard Study to evaluate emerging multi-cancer detection (MCD) technology. Guardant’s Shield™ MCD test was selected for use in the four-year study, which aims to enroll up to 24,000 patients and evaluate the use of MCD tests—blood tests that can screen for several types of cancer simultaneously—in future randomized controlled trials. Guardant’s Shield MCD test was chosen for the study based on the overall performance of its Shield platform in detecting 10 cancer types, including lung, breast, colorectal, prostate, bladder, ovarian, pancreatic, esophageal, liver and gastric. The data were presented at the 2025 American
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum